ReviewFrontiers in medicine2021
Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Kidney transplant outcomes in patients with complement dysregulation.World journal of transplantation · 2026Article
- Gemcitabine-sirolimus synergy associated thrombotic microangiopathy in a renal transplant recipient with mesenteric leiomyosarcoma: A case report.World journal of transplantation · 2026Article
- Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies.Clinical kidney journal · 2026Review
- Case Report: Avermectin poisoning-associated hemolytic uremic syndrome.Frontiers in immunology · 2026Article
- Cytomegalovirus viremia associated with systemic thrombotic microangiopathy after kidney transplantation: a case report.Frontiers in medicine · 2026Article
- Recurrent Postpartum Atypical Hemolytic Uremic Syndrome Caused by a C3 Pathogenic Variant: A Case Report.International journal of women's health · 2026Article
- The Role of the Endothelium as a Key Regulator of Chronic Transplant Rejection.Results and problems in cell differentiation · 2026Review
- Complement activation in secondary thrombotic microangiopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Two Cases of Post-Kidney Transplantation Thrombotic Microangiopathy From a Single Donor With Candidemia.Transplantation proceedings · 2025Article
- Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies.Childhood kidney diseases · 2025Review
- Perspective on Renal Involvement in Antiphospholipid Syndrome: Implications for Diagnosis, Pathogenesis, and Treatment.Journal of clinical medicine · 2025Review
- Post-transplant Thrombotic Microangiopathy.Journal of the American Society of Nephrology : JASN · 2025Review
- Atypical Hemolytic Uremic Syndrome: A Review of Complement Dysregulation, Genetic Susceptibility and Multiorgan Involvement.Journal of clinical medicine · 2025Review
- Thrombotic Microangiopathy After Kidney Transplantation: Insights Into Genetic Etiology and Clinical Outcomes.Kidney international reports · 2025Article
- Case Report: Effective use of eculizumab in treating recurrent atypical HUS following renal transplantation triggered by SARS-CoV-2 infection.Frontiers in medicine · 2025Article
- The outcome of thrombotic microangiopathy in kidney transplant recipients.BMC nephrology · 2024Article
- Everolimus-Associated Thrombotic Microangiopathy Following Renal Transplant: A Case Report.Cureus · 2024Article
- Thrombotic microangiopathy associated with calcineurin inhibitor induction doses in patients with a kidney transplant.Clinical case reports · 2024Article
- Response to Letter to the Editor From Bouwmeester RN et al.: "Eculizumab in Postransplant TMA: Unproven Benefit."Kidney international reports · 2024Article
- Eculizumab in Posttransplant TMA: Unproven Benefit: A Response to Maritati et al.: "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy.Kidney international reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant recipients. It appears in 0.8-14% of transplanted patients and negatively affects graft and patient survival. It can appear in a systemic form, with hemolytic microangiopathic anemia, thrombocytopenia, and renal failure, or in a localized form, with progressive renal failure, proteinuria, or arterial hypertension. Post-transplant thrombotic microangiopathy is classified as recurrent atypical hemolytic uremic syndrome or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.